- Home
- FREY vs GNFT Comparison
FREY vs GNFT Comparison
Compare FREY & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FREY
- GNFT
- Stock Information
- Founded
- FREY 2018
- GNFT 1999
- Country
- FREY Luxembourg
- GNFT France
- Employees
- FREY N/A
- GNFT N/A
- Industry
- FREY Industrial Machinery/Components
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FREY Miscellaneous
- GNFT Health Care
- Exchange
- FREY Nasdaq
- GNFT Nasdaq
- Market Cap
- FREY 364.9M
- GNFT 190.6M
- IPO Year
- FREY N/A
- GNFT 2019
- Fundamental
- Price
- FREY $3.03
- GNFT $3.71
- Analyst Decision
- FREY
- GNFT Strong Buy
- Analyst Count
- FREY 0
- GNFT 1
- Target Price
- FREY N/A
- GNFT $13.00
- AVG Volume (30 Days)
- FREY 3.2M
- GNFT 7.9K
- Earning Date
- FREY 11-06-2024
- GNFT 09-19-2024
- Dividend Yield
- FREY N/A
- GNFT N/A
- EPS Growth
- FREY N/A
- GNFT N/A
- EPS
- FREY N/A
- GNFT 0.47
- Revenue
- FREY N/A
- GNFT $86,225,222.00
- Revenue This Year
- FREY N/A
- GNFT $155.44
- Revenue Next Year
- FREY $414.23
- GNFT N/A
- P/E Ratio
- FREY N/A
- GNFT $7.55
- Revenue Growth
- FREY N/A
- GNFT 175.45
- 52 Week Low
- FREY $0.91
- GNFT $3.31
- 52 Week High
- FREY $3.36
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- FREY 76.53
- GNFT 33.06
- Support Level
- FREY $1.56
- GNFT $3.63
- Resistance Level
- FREY $2.17
- GNFT $3.94
- Average True Range (ATR)
- FREY 0.28
- GNFT 0.13
- MACD
- FREY 0.13
- GNFT 0.03
- Stochastic Oscillator
- FREY 81.96
- GNFT 19.17
About FREY FREYR Battery Inc.
FREYR Battery Inc is an emerging producer of clean battery solutions for the planet. It designs and manufactures high-density and cost-competitive lithium-ion batteries with a reduced carbon footprint for the markets for electric mobility, stationary energy storage, and marine and aviation applications.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.